Host-targeted Approaches
for Prevention and treatment
of Hospital-Acquired
Pneumonia

News & events

News & Events

1. Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation Pr. Roquilly and colleagues are publishing an article in Intensive Care Medecine journal. In this publication, they were able to identify two robust clinical subphenotypes by extensively analyzing HAP data sets....

HAP² project

“HAP2” is a 5-year project involving 10 partners from 6 countries, which aims to develop host-directed drugs and biomarkers to enhance the prevention and treatment of hospital-acquired pneumonia (HAP): an infectious disease of major concern for Europe, and develop precision medicine in infectious diseases.

HAP?

HAP is defined as a respiratory tract infection that occurs 48 hours or more after hospital admission. It is the most frequent cause of hospital-acquired infections and the main cause of antibiotics consumption in European hospitals.

5 years

2020 > 2024

600

Patients

10

Partners

6

Countries

Funding :

9 996 350€

Partners